Stacytine 200

OTC

Indications

• Treatment of bronchial secretion disorders, in particular during acute bronchial affections: Acute bronchitis and acute episode of chronic bronchopneumopathy.

Dosage

• Adults and children over 7 years old: 1 tablet 3 times a day.
• Children from 2 to 7 years old: 1 tablet (200 mg) twice a day.
• The duration of treatment will not exceed 8 to 10 days without medical advice.

Usage

• Administered orally. Dissolve the effervescent tablet in half a glass of water.

• Hypersensitivity to acetylcysteine or to any of the ingredients.
• Infant under 2 years of age.

• Risk of bronchial congestion especially in infants and in some patients unable to effectively sputum.
• Allergic skin reactions such as pruritus, rash erythematous, urticaria and angioedema.
• Possibility of digestive intolerance phenomena (gastric pain, nausea, diarrhea). It is advisable to reduce the dose.

• The association of bronchial mucomodifiers with cough suppressants and/or secretion-drying substances (atropine) is irrational.
• Mucolytics should not be used in infants.
• Treatment should be reassessed if symptoms or pathology persist or worsen.
• Stacytine 200 contains sorbitol. Patients with hereditary fructose intolerance (HFI) should not take/be given this medicinal product.
• Stacytine 200 contains aspartame, may be harmful if you have phenylketonuria (PKU), a rare genetic disorder in which phenylalanine builds up because the body cannot remove it properly.
• Stacytine 200 contains sodium benzoate which may increase jaundice (yellowing of the skin and eyes) in newborn babies (up to 4 weeks old).
• Caution is advised in subjects with peptic ulcer disease.
• The use of acetylcysteine should only be considered during pregnancy if necessary.
• Breastfeeding is possible during acetylcysteine administration.
• Patients should be aware of how they react to drug before driving or operating machinery.